Oncodesign Services SA

Established in Dijon, France, in 1995, Oncodesign Société Anonyme is a biopharmaceutical firm dedicated to the discovery and advancement of innovative therapeutic and diagnostic solutions. The company provides comprehensive research and development services to a broad spectrum of partners, including pharmaceutical and biotechnology companies, public research institutions, and investment groups. Its extensive service offerings span integrated drug discovery, in vitro and in vivo pharmacology, studies on drug candidate metabolism and pharmacokinetics, and the identification of translational biomarkers. Furthermore, Oncodesign specializes in biodecontamination, biosafety, biobanking, detailed analysis of new chemical and biological entities (including membrane proteins), and immunological and microbiological monitoring. Beyond its service activities, Oncodesign is actively involved in developing its own kinase inhibitor programs and licensing these technologies for applications in oncology, central nervous system disorders, and inflammation. The company maintains significant collaborations, including a strategic partnership with InterSystems focused on oncology treatments, another with Covalab, and a specific agreement with TiumBio Co., Ltd. for the joint research and development of fibrosis drug candidates.